Next-generation platform for allogenic T-cell therapy

Enabling the immune system

More Information

Next-generation platform for allogenic T-cell therapy

Bringing cancer cure one step closer to reality

More Information

About Us

Enabling a new frontier in T-cell immunotherapy for currently incurable diseases by providing game-changing treatment solutions and improving outcomes for cancer patients with the highest unmet medical needs.

Our aim is to become a major player in the field of cancer cell therapy by being the leading allogenic cell therapy platform combining bispecific antibodies with allogenic cell therapy.

More Information

Technology

More Information

The ENABLR technology platform provides an off-the-shelf solution ideally suited to boost T-cell based therapies.

1

T cells are collected from an allogenic healthy donor

2

Cells are modified by replacing the wild type T-cell receptor with a blunted receptor without variable domains

3

In combination with a CD3xTAA bispecific antibody, cells areactivatedand eliminate the cancer cells

Our Team

Rainer Henning

PhD. , Chief Executive Officer

Muhammad Yassin

MD/PhD, Chief Scientific Officer, Co-Founder

Muneer Sawaied

M.D, Chief Operating Officer

Program

GY 101 ENABLR +CD3xBCMA
GY 201 ENABLR +CD3xCD20
GY 301 ENABLR +CD3 x DLL3
GY 401 ENABLR +CD3xGPC3

Indication

>Multiple MyelomaRelapsing/Refractory (RRMM)
>CD20 lymphomaRelapsing/Refractory
>Small cell lung cancer(SCLC)
>Hepatocellular CarcinomaHCC

Development Stage

Discovery

Preclinical

Phase l

Phase lI

2024

2027

2024

2027

2024

2028

2024

2028

News and Announcements

View All

Next-generation platform for allogenic T-cell therapy

Enabling the immune system

Next-generation platform for allogenic T-cell therapy

Bringing cancer cure one step closer to reality

A game-changing treatment

for patients with the greatest unmet medical needs

Strong Team

Highly experienced CEO and pioneering founder team

About Us

Technology

The ENABLR technology platform provides an off-the-shelf solution ideally suited to boost T-cell based therapies.

T cells are collected from an allogenic healthy donor

Cells are modified by replacing the wild type T-cell receptor with a blunted receptor without variable domains

In combination with a CD3xTAA bispecific antibody, cells areactivatedand eliminate the cancer cells

Our Team

Rainer Henning

PhD. , Chief Executive Officer

Muhammad Yassin

MD/PhD, Chief Scientific Officer, Co-Founder

Muneer Sawaied

M.D, Chief Operating Officer

Program

Indication

Development Stage

Discovery

Preclinical

Phase l

Phase lI

News and Announcements

SMiLEBOOTCAMP

We are pleased to announce that we have been selected as one...

Irish Times Life Sciences and Healthcare award

It is with great pleasure that we announce that Genicity has won...

BioTechBootcamp

#BioTechBootcamp - Done Merck Prize - DoneIt was eight weeks of intensive training, coaching,...

Get in Touch With Us

You can contact us for any inquiries and needs regarding Cell Therapy, Allogeneic Treatment, Immunotherapy, and Genetic Therapy.

Get in Touch

Next-generation platform for allogenic T-cell therapy

Enabling the immune system

Next-generation platform for allogenic T-cell therapy

Bringing cancer cure one step closer to reality

A game-changing treatment

for patients with the greatest unmet medical needs

Strong Team

Highly experienced CEO and pioneering founder team

About Us

Technology

The ENABLR technology platform provides an off-the-shelf solution ideally suited to boost T-cell based therapies.

T cells are collected from an allogenic healthy donor

Cells are modified by replacing the wild type T-cell receptor with a blunted receptor without variable domains

In combination with a CD3xTAA bispecific antibody, cells areactivatedand eliminate the cancer cells

Our Team

Rainer Henning

PhD. , Chief Executive Officer

Muhammad Yassin

MD/PhD, Chief Scientific Officer, Co-Founder

Muneer Sawaied

M.D, Chief Operating Officer

Program

Indication

Development Stage

Discovery

Preclinical

Phase l

Phase lI

News and Announcements

SMiLEBOOTCAMP

We are pleased to announce that we have been selected as one...

Irish Times Life Sciences and Healthcare award

It is with great pleasure that we announce that Genicity has won...

BioTechBootcamp

#BioTechBootcamp - Done&nbsp;Merck Prize - DoneIt&nbsp;was eight weeks of intensive training, coaching,...

Get in Touch With Us

You can contact us for any inquiries and needs regarding Cell Therapy, Allogeneic Treatment, Immunotherapy, and Genetic Therapy.

Get in Touch

#BioTechBootcamp - Done Merck Prize - DoneIt was eight weeks of intensive training, coaching,...